260552-98-5

Basic information

• Product Name: 2,6-DIFLUORO-3-NITROBENZOYL CHLORIDE
• Synonyms: 2,6-DIFLUORO-3-NITROBENZOYL CHLORIDE
• CAS NO: 260552-98-5
• Molecular Formula: C₇H₂ClF₂NO₃
• Molecular Weight: 221.55
• Mol File: 260552-98-5.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,6-DIFLUORO-3-NITROBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DIFLUORO-3-NITROBENZOYL CHLORIDE(260552-98-5)
• EPA Substance Registry System: 2,6-DIFLUORO-3-NITROBENZOYL CHLORIDE(260552-98-5)

Safety Data

• Hazardous Substances Data: 260552-98-5(Hazardous Substances Data)

Usage

Uses

2,6-Difluoro-3-nitrobenzoyl Chloride could be useful for inhibiting GCN2 activity.

Upstream product

• 83141-10-0 2,6-difluoro-3-nitrobenzoic acid 
• 385-00-2 2,6-difluorobenzoic acid 
• 446-35-5 2,4-Difluoronitrobenzene 
• 1309431-02-4 benzyl 2,6-difluoro-3-nitrobenzoate 

Downstream Products

• 535170-20-8 tert-butyl (3-amino-2,6-difluorophenyl)carbamate 
• 179739-64-1 1-(3-amino-2,4-difluorophenyl)-7-chloro-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 
• 179739-63-0 ethyl 1-(3-tert-butoxycarbonylamino-2,4-trifluorophenyl)-7-chloro-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate 
• 179739-88-9 1-(3-amino-2,4-difluorophenyl)-7-[(3S)-3-aminopyrrolidin-1-yl]-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid 
• 1254567-31-1 (2,6-difluoro-3-nitro-phenyl)-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-methanone 
• 1254567-35-5 (3-amino-2,6-difluorophenyl)(5-iodo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone 
• 1312942-08-7 (3-amino-2,6-difluoro-phenyl)-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-methanone 
• 1312942-09-8 (3-amino-2,6-difluoro-phenyl)-[5-(2-methyl-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-methanone 
• 1312940-72-9 N-{2,4-difluoro-3-[5-(2-methyl-pyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-phenyl}-2-fluoro-benzenesulfonamide 
• 1312942-07-6 (2,6-difluoro-3-nitrophenyl)(5-iodo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone 
• 1309431-04-6 3-(3-amino-2,6-difluoro-benzoyl)-4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile 
• 1309431-03-5 4-chloro-3-(2,6-difluoro-3-nitro-benzoyl)-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile 
• 1380229-22-0 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)-1-methyl-1H-pyrazole-4-sulfonamide 
• 1380228-63-6 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)-1-methyl-1H-pyrazole-4-sulfonamide 

Relevant articles and documents

Synthesis of novel 8-nitro-substituted 1,3-benzothiazin-4-ones

New 2,5-bis(azacyclohex-1-yl)-8-nitro-1,3-benzothiazin-4-ones were synthesized from 2,6-difluorobenzoic acid in two preparative stages. The ethoxycarbonylpiperazino derivative surpasses in tuberculostatic activity (MIC 4 μg ml?1) its 5-fluoro-8-H-counterpart. The first representative of 5-fluoro-8-nitro-1,3-benzothiazin-4-ones was obtained through the condensation of 2,6-difluoro-3-nitrobenzoyl isothiocyanate and N-methylindole.

Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF

Several pyrrolo[2,3-b]pyridine-based B-RAF inhibitors are well known and some of them are currently FDA approved as anticancer agents. Based on the structure of these FDA approved V600EB-RAF inhibitors, two series of pyrrolo[2,3-b]pyridine scaffold were designed and synthesized in attempt to develop new potent V600EB-RAF inhibitors. The 38 synthesized compounds were biologically evaluated for their V600EB-RAF inhibitory effect at single dose (10 μM). Compounds with high percent inhibition were tested to determine their IC50 over V600EB-RAF. Compounds 34e and 35 showed the highest inhibitory effect with IC50 values of 0.085 μM and 0.080 μM, respectively. Headed for excessive biological evaluation, the synthesized derivatives were tested over sixty diverse human cancer cell lines. Only compound 35 emerged as a potent cytotoxic agent against different panel of human cancer cell lines.

Boosting the efficacy of anti-MRSA β-lactam antibiotics via an easily accessible, non-cytotoxic and orally bioavailable FtsZ inhibitor

The rapid emergence of methicillin-resistant Staphylococcus aureus (MRSA) strains has undermined the therapeutic efficacy of existing β-lactam antibiotics (BLAs), prompting an urgent need to discover novel BLAs adjuvants that can potentiate their anti-MRSA activities. In this study, cytotoxicity and antibacterial screening of a focused compound library enabled us to identify a compound, namely 28, which exhibited low cytotoxicity against normal cells and robust in vitro bactericidal synergy with different classes of BLAs against a panel of multidrug-resistant clinical MRSA isolates. A series of biochemical assays and microscopic studies have revealed that compound 28 is likely to interact with the S. aureus FtsZ protein at the T7-loop binding pocket and inhibit polymerization of FtsZ protein without interfering with its GTPase activity, resulting in extensive delocalization of Z-ring and morphological changes characterized by significant enlargement of the bacterial cell. Animal studies demonstrated that compound 28 had a favorable pharmacokinetic profile and exhibited potent synergistic efficacy with cefuroxime antibiotic in a murine systemic infection model of MRSA. Overall, compound 28 represents a promising lead of FtsZ inhibitor for further development of efficacious BLAs adjuvants to treat the staphylococcal infection.